Recent News

• 05.08.2025 - Theravance Biopharma First Quarter 2025 Earnings Results Call
• 04.24.2025 - Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
• 04.07.2025 - Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
• 03.31.2025 - Theravance Biopharma to Participate in an Upcoming Investor Conference
• 03.27.2025 - Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - Theravance Biopharma Fourth Quarter 2024 Earnings Results Call
• 02.26.2025 - Theravance Biopharma Fourth Quarter 2024 Earnings Results Call
• 02.26.2025 - Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Recent Filings

• 04.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 04.10.2025 - DEF 14A Other definitive proxy statements
• 03.07.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.26.2025 - 8-K Current report
• 02.26.2025 - EX-99.1 EX-99.1